NeoGenomics, Inc.: NeoGenomics to Acquire Inivata - Combining Best-In-Class Liquid Biopsy Technology with Leading Community Oncology Platform
NeoGenomics exercises option struck in May 2020 to purchase remaining equity stake for $390 million
Completes $200 million strategic financing with leading oncology-focused specialist investors
FT. MYERS, FL / ACCESSWIRE / May 5, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced today that it has agreed to acquire Inivata Ltd, a global, commercial stage liquid biopsy platform company headquartered in Cambridge, England. The acquisition follows a $25 million minority equity investment by NeoGenomics in Inivata in May 2020, at which time NeoGenomics was granted a fixed price option to purchase the remainder of Inivata for $390 million prior to December 31, 2021. The cash purchase price will be funded with balance sheet cash and through
Inivata to be Acquired by NeoGenomics
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
NeoGenomics Announces the Launch of Biomarker Assist KRAS Single Gene Testing (SGT) Program for Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer Patients
newjerseytelegraph.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from newjerseytelegraph.com Daily Mail and Mail on Sunday newspapers.
NeoGenomics, Inc : NeoGenomics Announces the Launch of Biomarker Assist KRAS Single Gene Testing (SGT) Program for Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer Patients
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.